Center for Regenerative Medicine in Barcelona, Barcelona, Spain.
PLoS One. 2010 Sep 17;5(9):e12664. doi: 10.1371/journal.pone.0012664.
After the hope and controversy brought by embryonic stem cells two decades ago for regenerative medicine, a new turn has been taken in pluripotent cells research when, in 2006, Yamanaka's group reported the reprogramming of fibroblasts to pluripotent cells with the transfection of only four transcription factors. Since then many researchers have managed to reprogram somatic cells from diverse origins into pluripotent cells, though the cellular and genetic consequences of reprogramming remain largely unknown. Furthermore, it is still unclear whether induced pluripotent stem cells (iPSCs) are truly functionally equivalent to embryonic stem cells (ESCs) and if they demonstrate the same differentiation potential as ESCs. There are a large number of reprogramming experiments published so far encompassing genome-wide transcriptional profiling of the cells of origin, the iPSCs and ESCs, which are used as standards of pluripotent cells and allow us to provide here an in-depth analysis of transcriptional profiles of human and mouse cells before and after reprogramming. When compared to ESCs, iPSCs, as expected, share a common pluripotency/self-renewal network. Perhaps more importantly, they also show differences in the expression of some genes. We concentrated our efforts on the study of bivalent domain-containing genes (in ESCs) which are not expressed in ESCs, as they are supposedly important for differentiation and should possess a poised status in pluripotent cells, i.e. be ready to but not yet be expressed. We studied each iPSC line separately to estimate the quality of the reprogramming and saw a correlation of the lowest number of such genes expressed in each respective iPSC line with the stringency of the pluripotency test achieved by the line. We propose that the study of expression of bivalent domain-containing genes, which are normally silenced in ESCs, gives a valuable indication of the quality of the iPSC line, and could be used to select the best iPSC lines out of a large number of lines generated in each reprogramming experiment.
在 20 年前胚胎干细胞为再生医学带来希望和争议之后,多能细胞研究出现了新的转折,当时 Yamanaka 小组报告说,仅用四种转录因子就可以将成纤维细胞重编程为多能细胞。此后,许多研究人员设法将来自不同来源的体细胞重编程为多能细胞,但重编程的细胞和遗传后果在很大程度上仍不清楚。此外,诱导多能干细胞 (iPSC) 是否真的与胚胎干细胞 (ESC) 功能等效,以及它们是否表现出与 ESC 相同的分化潜力仍不清楚。迄今为止,已经发表了大量的重编程实验,涵盖了起始细胞、iPSC 和 ESC 的全基因组转录谱分析,这些细胞被用作多能细胞的标准,并使我们能够在这里对人类和小鼠细胞重编程前后的转录谱进行深入分析。与 ESC 相比,iPSC 如预期的那样,共享一个共同的多能性/自我更新网络。也许更重要的是,它们在一些基因的表达上也存在差异。我们集中精力研究二价结构域基因(在 ESC 中)的表达,这些基因在 ESC 中不表达,因为它们对分化很重要,应该在多能细胞中处于启动状态,即准备表达但尚未表达。我们分别研究每个 iPSC 系,以估计重编程的质量,并看到每个相应的 iPSC 系中表达的此类基因数量最少与该系达到的多能性测试严格性之间存在相关性。我们提出,研究二价结构域基因的表达,这些基因在 ESC 中通常被沉默,可以为 iPSC 系的质量提供有价值的指示,并可用于从每个重编程实验中产生的大量系中选择最佳的 iPSC 系。